A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival

• DOI: 10.3389/fgene.2022.991706
• Publication Date: 2022-10-21T06:56:53Z
• Authors: Carlos A. Barrón-...; Mariel Garcia-Cha...; Andres J. Morán-M...; Raul Delgadillo-C...; María G. Martínez...; María M. Villaseñ...; Adriana Aguilar-L...; Luis F. Jave-Suárez
• Keywords: 0301 basic medicine; 03 medical and health sciences; breast cancer; overall survival; Genetics; biomarkers; bioinformatics; RNA-seq; QH426-470; neoadjuvant chemotherapy; 3. Good health

Breast cancer ranks first in terms of mortality and incidence rates worldwide among women. The HER2+ molecular subtype is one the most aggressive subtypes; its treatment includes neoadjuvant chemotherapy use a HER2 antibody. Some patients develop resistance despite positive results obtained using this therapeutic strategy.To identify prognostic markers for survival patients.Patients treated with were assigned to sensitive resistant groups based on their response. Differentially expressed genes (DEGs) identified RNA-seq analysis. KEGG pathway, gene ontology, interactome analyses performed all DEGs. An enrichment analysis Gene set was performed. All DEGs analyzed overall (OS) disease-free (DFS).A total 94 related resistance. Survival showed that 12 (ATF6B, DHRS13, DIRAS1, ERAL1, GRIN2B, L1CAM, IRX3, PRTFDC1, PBX2, S100B, SLC9A3R2, TNXB) good predictors survival, eight (GNG4, IL22RA2, MICA, SERPINF2, HLA-A, (OS).We highlighted expression signature can differentiate response, DFS breast cancer.